Price
Target price
€74.00
€74.00
0.680%
0.5
0.680%
€70.96
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Protagonist
sharewise wants to provide you with the best news and tools for Protagonist, so we directly link to the best financial data sources.
Financials
News
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Recent market speculation linking Johnson & Johnson (NYSE: JNJ) to a complete acquisition of its partner, Protagonist Therapeutics (NASDAQ: PTGX), offers a valuable glimpse into a core corporate
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
Clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense
Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist Therapeutics (NASDAQ:PTGX), a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025